14:00 EST Alterity CEO says to meet with FDA, move forward with Phase 3 study
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
- Alterity Therapeutics reports cash balance of A$54.46M as of September 30
- Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds
- Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
- Alterity Therapeutics presents data from ATH434 Phase 2 trial